ISRCTN61893718已完成未知
Microarray Analysis in breast cancer to Taylor Adjuvant Drugs Or Regimens, a randomized phase III study
etherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI AVL)0 个研究点目标入组 664 人开始时间: 2005年12月20日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 664
研究概览
简要总结
2017 Results article in https://www.ncbi.nlm.nih.gov/pubmed/29371927 results (added 16/01/2019) 2018 Results article in https://www.ncbi.nlm.nih.gov/pubmed/30125761 results (added 16/01/2019) 2024 Results article in https://pubmed.ncbi.nlm.nih.gov/39206149/ (added 02/09/2024)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •Current inclusion criteria as of 29/04/2013:
- •1. Women with pT1-T3, pN0-3b, M0 adenocarcinoma of the breast (TNM classification 2002). Women with a macrometastasis in the sentinel node, who did not receive an axillary dissection (pN1(sn)), are only eligible if radiotherapy of the axilla is included in the treatment plan (for instance experimental arm AMAROS study);
- •2. Known HER2 and estrogen receptor status.
- •3. Frozen tumor tissue available (or tumor tissue sent in RNAlater to NKI-AVL).
- •4. primary surgery (defined as date of last surgical intervention) < 6 weeks before randomisation, or radiotherapy < 5 weeks before randomisation.
- •5. Good performance status (WHO < 1)
- •6. normal hematology, normal renal and liver function tests (see below).
- •7. no history of heart failure.
- •8. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures during study treatment (chemotherapy and hormonal therapy).
- •9. no conditions that may compromise follow-up.
- •10. informed consent.
- •11. At least 18 years old and able to undergo intensive chemotherapy (in the study of Martin et al. employing the TAC regimen (1d) age < 65 years was required).
- •12. Laboratory requirements: (within 14 days prior to registration)
- •12.1. Hematology:
- •12.1.1. Neutrophils = 1.5 109/L;
- •12.1.2. Platelets = 100 109/L;
- •12.1.3. Hemoglobin =6.0 mmol/L;
- •12.2. Hepatic function:
- •12.2.1. Total bilirubin = 16 umol/L;
- •12.2.2. ASAT (SGOT) and ALAT (SGPT) = 1.5 UNL;
- •12.2.3. Alkaline phosphatase = 2.5 UNL;
- •12.3. Renal function:
- •12.3.1. Creatinine = 120 µmol/L;
- •12.3.2. If limit values, the calculated creatinine clearance should be = 60 mL/min.
- •Previous inclusion criteria until 29/04/2013:
- •1. Women with pT0-T3, pN 1-3b, M0 adenocarcinoma of the breast (TNM classification 2002). Women with a macrometastasis in the sentinel node, who did not receive an axillary dissection (pN1(sn)), are only eligible if radiotherapy of the axilla is included in the treatment plan (for instance experimental arm AMAROS study).
- •2. Frozen tumor tissue available (or tumor tissue sent in RNAlater to NKI-AVL)
- •3. Primary surgery <6 weeks before randomisation, or radiotherapy <5 weeks before randomisation
- •4. Good performance status; WHO <1
- •5. Normal hematology, normal renal and liver function tests (see below)
- •6. No history of heart failure
- •7. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures during study treatment (chemotherapy and hormonal therapy)
- •8. No conditions that may compromise follow-up
- •9. Written Informed consent
- •10. Able to undergo intensive chemotherapy (in the study of Nabholtz (1) age <65 years was required)
- •11. Laboratory requirements: (within 14 days prior to registration)
- •Hematology:
- •i. Neutrophils >1.5 x 10^9/l
- •ii. Platelets >100 x 10^9/l
- •iii. Hemoglobin >6.0 mmol/l
- •Hepatic function:
- •i. Total bilirubin <16 µmol/L
- •ii. ASAT (SGOT) and ALAT (SGPT) <1.5 UNL
- •iii. Alkaline phosphatase <2.5 UNL
- •Renal function:
- •i. Creatinine <120 µmol/l
- •ii. If limit values, the calculated creatinine clearance should be >60 ml/min
排除标准
- •Current exclusion criteria as of 29/04/2013:
- •1. Prior systemic anticancer therapy for any cancer (immunotherapy, hormonal therapy, chemotherapy)
- •2. Prior radiation therapy for breast cancer
- •3. HER2 positive breast cancer (except for patients who are going to be treated according to HERA study (1c)
- •4. Pregnant, or lactating patients
- •5. Pre-existing motor or sensory neurotoxicity of a severity > grade 2 by NCI criteria
- •6. Other serious illness or medical condition:
- •6.1. Congestive heart failure or unstable angina pectoris, previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or high-risk uncontrolled arrhythmias
- •6.2. History of significant neurological or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent
- •6.3. Active uncontrolled infection
- •7. Past history of invasive breast cancer or past or current history of neoplasm other than breast carcinoma, except for:
- •7.1. Curatively treated non-melanoma skin cancer
- •7.2. In situ carcinoma of the cervix
- •7.3. Ipsilateral ductal carcinoma in-situ (DCIS) of the breast
- •7.4. Lobular carcinoma in-situ (LCIS) of the breast
- •8. Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry
- •9. Male patients
- •Previous exclusion criteria until 29/04/2013:
- •1. Prior systemic anticancer therapy for any cancer (immunotherapy, hormonal therapy, chemotherapy)
- •2. Prior radiation therapy for breast cancer
- •3. Pregnant, or lactating patients
- •4. Pre-existing motor or sensory neurotoxicity of a severity > grade 2 by NCI criteria
- •5. Other serious illness or medical condition:
- •5.1 Congestive heart failure or unstable angina pectoris, previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or high-risk uncontrolled arrhythmias
- •5.2 A history of significant neurological or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent
- •5.3 Active uncontrolled infection
- •6. Past or current history of neoplasm other than breast carcinoma, except for:
- •6.1 Curatively treated non-melanoma skin cancer
- •6.2 In situ carcinoma of the cervix, cipsilateral ductal carcinoma in-situ (DCIS) of the breast,
- •6.3 Llobular carcinoma in-situ (LCIS) of the breast
- •7. Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry.
- •8. Male patients
研究者
相似试验
已完成
不适用
Microarray Analysis in breast cancer to Tailor Adjuvant Drugs Or Regimens, a randomized phase III study.Primary operable breast cancerNL-OMON23149etherlands Cancer Institute-Antoni van Leeuwenhoek Hospital660
已完成
不适用
The implementation of microarrays in cancer diagnosis (microarray prognostics in breast cancer)CancerBreast cancerISRCTN71917916etherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI AVL) (The Netherlands)750
进行中（未招募）
不适用
Breast cancer biomarkers and treatment targetsMalignant neoplasm of breastBreast cancerCancerISRCTN40576403niversity Hospital Southampton (UK)500
进行中（未招募）
不适用
Microarray Evaluaton of Normal Breast Tissue to Identify Genetic Markers of Risk for Estrogen Receptor Positive Breast CancerCancer - BreastInvasive Breast CancerACTRN12605000480684SSWAHS100
已完成
不适用
Molecular Analysis of Breast CancerBreast Cancer Non-invasive Breast CancerBreast Cancer Early Stage Breast Cancer (Stage 1-3)Breast CancerNCT00569049Stanford University788